Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a smartphone app tame acid reflux and restore sleep?

NCT ID NCT07744815

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests whether a mobile app can help people with gastroesophageal reflux disease (GERD) reduce symptom recurrence and improve sleep quality and quality of life. Participants with confirmed GERD will be randomly assigned to either use the app—which provides education, lifestyle and diet tips, breathing exercises, and reminders—or receive standard education. Over eight weeks, researchers will track changes in symptoms, sleep, and daily functioning to see if the app offers added benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A mobile application providing GERD education, lifestyle and dietary guidance, diaphragmatic breathing exercises, and reminders
What this could lead to
If effective, this app could offer a simple, accessible way for people with GERD to reduce symptom flare-ups and improve sleep and daily well-being.
What could go wrong
The trial is relatively small and the app's benefits may be modest or not last beyond the study period. Success depends on participants consistently using the app.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Sep 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 60 years. * Able to communicate in Mandarin Chinese or Taiwanese. -.Owns and is able to use a smartphone. * Endoscopically confirmed gastroesophageal reflux disease with Los Angeles (LA) Classification Grade B, C, or D erosive esophagitis, or Barrett's esophagus. * Able and willing to provide written informed consent. Exclusion Criteria: * Previous esophageal or gastric surgery, including anti-reflux surgery. * Regular use of proton pump inhibitors within the previous 8 weeks. * Receiving antithrombotic therapy. * Diabetes mellitus requiring treatment (HbA1c ≥ 6.5%). * Liver cirrhosis (Child-Pugh class B or higher). * Chronic kidney disease stage 3 or higher. * Neurological disorders affecting participation. * Malignancy other than early-stage cancer. * Hiatal hernia larger than 2 cm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal reflux esophagitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yuan's General Hospital

    Kaohsiung City, 80249, Taiwan